Aristides Capital LLC Invests $202,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Aristides Capital LLC purchased a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 8,000 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CLDX. American Century Companies Inc. boosted its position in shares of Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock valued at $15,376,000 after acquiring an additional 193,093 shares during the period. Sovran Advisors LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter worth $2,867,000. Fisher Asset Management LLC raised its stake in Celldex Therapeutics by 20.9% in the fourth quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company’s stock valued at $11,435,000 after purchasing an additional 78,145 shares in the last quarter. Barclays PLC lifted its position in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after purchasing an additional 76,207 shares during the period. Finally, Cinctive Capital Management LP grew its stake in Celldex Therapeutics by 140.6% during the fourth quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company’s stock worth $2,055,000 after buying an additional 47,523 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CLDX shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target for the company. Morgan Stanley began coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 price objective for the company. Finally, The Goldman Sachs Group decreased their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.33.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX opened at $15.73 on Tuesday. Celldex Therapeutics, Inc. has a 52 week low of $14.61 and a 52 week high of $47.00. The firm has a market cap of $1.04 billion, a PE ratio of -6.12 and a beta of 1.59. The firm’s fifty day moving average is $21.01 and its 200-day moving average is $25.16.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.